Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration April 28, 2021
Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021 April 27, 2021
Ultragenyx Completes Successful End-of-Phase 2 Meeting with FDA and Finalizes Phase 3 Study Design for DTX301 Ornithine Transcarbamylase (OTC) Gene Therapy Program April 22, 2021
Beam Therapeutics Publishes Data Highlighting Ability to Rationally Design Base Editors for Precise Editing April 20, 2021
Citrine Medicine and Sinopharm Group Announce Strategic Partnership to Broaden and Accelerate Access to Rare Disease Drugs in China April 19, 2021
Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021 April 13, 2021